Nano-X Imaging Ltd. - NNOX STOCK NEWS

Nanox Imaging (Nasdaq: NNOX) announced that data from five studies supporting its AI Cardiac Solution, HealthCCSng, will be presented at the 19th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT) from July 18-21 in Washington, D.C.

These studies are by institutions including Brigham & Women’s Hospital, Einstein Jefferson Medical Center, Corewell Health, Massachusetts General Hospital, and Beilinson Medical Center. HealthCCSng uses routine chest CT scans to quantify coronary artery calcium (CAC) levels, a strong predictor of future cardiac events. Patients with high CAC are up to 6x more likely to suffer from cardiac events.

Key presentations include: 'The Frequency, Prevalence, And Outcomes of Incidentally Detected Coronary Artery Calcium Using AI Analysis' by Brittany Weber (July 20, 10:30 AM), and 'Optimizing Preventive Cardiology: Harnessing AI for Early Detection of CAD' by Dr. Chiduzie Madubata (July 19, 9:30 AM - 10:15 AM).

Nano-X Imaging announced the integration of AI solutions into its Second Opinions platform, enhancing its teleradiology services. This advancement leverages deep-learning AI from Nanox.AI to analyze chest and abdominal CT scans, aiming to detect chronic conditions early. The platform, managed by USARAD Holdings, now includes FDA-cleared AI tools: HealthCCSng for coronary artery disease, HealthOST for osteoporosis risk, and HealthFLD for fatty liver disease. These AI findings are vetted by physicians and integrated into patient reports.

Nanox Imaging announced its Q1 2024 financial results, reporting revenues of $2.6 million, up from $2.4 million in Q1 2023. However, the net loss increased to $12.2 million from $11.8 million in the previous year. The company secured agreements with Dandelion Health and Covera Health for its AI solutions and demonstrated its Nanox.ARC scanning technology in New Jersey. Nanox also entered a partnership with Swissray to improve customer support. Despite a decrease in research and administrative expenses, gross loss increased significantly. Cash reserves dropped to $73.3 million from $82.8 million at the end of 2023.

Nanox Imaging, a medical imaging technology company, will announce its financial results for Q1 2024 on May 28, 2024. The report, covering the period ending March 31, 2024, will be released before the market opens. CEO Erez Meltzer and CFO Ran Daniel will host a conference call at 8:30 a.m. ET to review the results and provide a business update. Interested parties can register for the call or access the live webcast via links available on Nanox's Investor Relations section.

NANO-X IMAGING , the innovative medical imaging technology company, announced that its teleradiology subsidiary, USARAD Holdings, Inc., has been awarded The Joint Commission's Gold Seal of Approval for Ambulatory Health Care Accreditation for the sixth time. This accreditation reflects the organization's commitment to safe and quality patient care.

Nanox, a medical imaging technology company, is set to participate in three investor conferences in May 2024. The conferences include EF Hutton 2024 Annual Global Conference, AGP 2024 Healthcare Conference, and Benchmark 2024 Healthcare House Call Virtual Conference.

NANO-X IMAGING (NNOX) filed its 2023 Annual Report on Form 20-F with the SEC, including audited financial statements. Shareholders can access the report on the SEC and company websites. Hard copies are available upon request.

Nanox partners with AhealthZ and SCL Science to advance Nanox.ARC 3D imaging system and AI solutions in South Korea, aiming to secure local authorizations and licenses. The collaboration includes integration of Nanox's AI solutions in remote image analysis and potential integration of Nanox.MARKETPLACE with SCL Science's teleradiology centers.

Nanox launches Nanox.ARC in the United States with installations across five states, marking a major advancement in medical imaging management. The company generated $2.4 million in revenue in Q4 2023, showing growth from the previous year. Nanox.ARC systems have begun scanning patients in the US and passed required tests in three states. Nanox.AI secured FDA clearance for HealthFLD, an AI-based software for fatty liver disease assessment. The ADOPT study demonstrated a sixfold increase in identifying patients with vertebral compression fracture. Nanox continues to advance in clinical trials and regulatory processes, aiming to provide transformative healthcare solutions.